open access

Vol 6, No 1 (2017)
Original articles (submitted)
Published online: 2017-06-20
Get Citation

Evaluation of the quality of life and satisfaction with the therapy in patients with type 1 diabetes — is Medtronic MiniMed 640G system able to improve it? Preliminary insights

Aleksandra Tabor, Władysław Bartosz Gaweł, Oliwia Goik, Grażyna Deja, Przemysława Jarosz-Chobot
DOI: 10.5603/DK.2017.0002
·
Pubmed: 12376491
·
Clinical Diabetology 2017;6(1):1-7.

open access

Vol 6, No 1 (2017)
Original articles (submitted)
Published online: 2017-06-20

Abstract

Introduction. The quality of life (QoL) became a very important parameter in the XXI century which often decides about the type of treatment. The spectrum of treatment possibilities is constantly expanding due to the rapid technological development. Currently most up-to-date MiniMed 640G system which is able to predict hypoglycemia episode, flexibly and transiently stop insulin delivery before approaching programmed low glucose limit and automatically resume it (SmartGuard technology) can become a way to improve the QoL of diabetic patients.

Material and methods. The questionnaire survey was conducted among 10 girls and 14 boys at the age of 2–15 (median 8) years with well-controlled DM1 (HbA1c varied from 5.8 to 8.8%, mean 6.7%). The mean time from diagnosis was 3.7 years. The main inclusion criteria was the therapy with 640G system. Patients were previously treated with insulin pumps with or without hypoblocade (Paradigm® 722/MiniMed® Veo). 3–11 months after introducing 640G system to therapy during the follow-up visit two surveys were conducted simultaneously: PedsQLTM 3.0 Diabetes which measured the QoL in diabetic patients (Survey I) and the authorial questionnaire (Survey II) which measured the satisfaction of 640G therapy (consisted of 11 questions, 2 closed and 9 semi-closed-ended).

Results. Considering participants’ answers in Survey I, the mean scores of QoL regarding communication (79%), concerns (60%), treatment (76%) and diabe­tes (69%) which according to our scale (0–19% no impact, 20–39% low impact, 40–59% moderate impact, 60–79% high impact, 80–100% very high impact) proved that QoL was perceived high. The results of Survey II showed gladness and assur­ance of the patients with 640G therapy. Relying on their self-observation, over a half of participants (17 people) certified a serious reduction of both hypo/hyperglycemia episodes. 8 patients/caregivers highlighted a great coherence between blood glucose measured by sensor and glucose meter which enabled them to decrease the frequency of pricking fingers. 11 patients considered management of DM1 to be easier, they also noticed better cooperation with 640G system.

Conclusion. Patients with DM1 using 640G system are satisfied with the effects of the therapy, they feel safer and their QoL measured by PedsQL is relatively high.

Abstract

Introduction. The quality of life (QoL) became a very important parameter in the XXI century which often decides about the type of treatment. The spectrum of treatment possibilities is constantly expanding due to the rapid technological development. Currently most up-to-date MiniMed 640G system which is able to predict hypoglycemia episode, flexibly and transiently stop insulin delivery before approaching programmed low glucose limit and automatically resume it (SmartGuard technology) can become a way to improve the QoL of diabetic patients.

Material and methods. The questionnaire survey was conducted among 10 girls and 14 boys at the age of 2–15 (median 8) years with well-controlled DM1 (HbA1c varied from 5.8 to 8.8%, mean 6.7%). The mean time from diagnosis was 3.7 years. The main inclusion criteria was the therapy with 640G system. Patients were previously treated with insulin pumps with or without hypoblocade (Paradigm® 722/MiniMed® Veo). 3–11 months after introducing 640G system to therapy during the follow-up visit two surveys were conducted simultaneously: PedsQLTM 3.0 Diabetes which measured the QoL in diabetic patients (Survey I) and the authorial questionnaire (Survey II) which measured the satisfaction of 640G therapy (consisted of 11 questions, 2 closed and 9 semi-closed-ended).

Results. Considering participants’ answers in Survey I, the mean scores of QoL regarding communication (79%), concerns (60%), treatment (76%) and diabe­tes (69%) which according to our scale (0–19% no impact, 20–39% low impact, 40–59% moderate impact, 60–79% high impact, 80–100% very high impact) proved that QoL was perceived high. The results of Survey II showed gladness and assur­ance of the patients with 640G therapy. Relying on their self-observation, over a half of participants (17 people) certified a serious reduction of both hypo/hyperglycemia episodes. 8 patients/caregivers highlighted a great coherence between blood glucose measured by sensor and glucose meter which enabled them to decrease the frequency of pricking fingers. 11 patients considered management of DM1 to be easier, they also noticed better cooperation with 640G system.

Conclusion. Patients with DM1 using 640G system are satisfied with the effects of the therapy, they feel safer and their QoL measured by PedsQL is relatively high.

Get Citation

Keywords

hypoglycemia, quality of life, sensor- -augmented pump therapy, SmartGuard technology

About this article
Title

Evaluation of the quality of life and satisfaction with the therapy in patients with type 1 diabetes — is Medtronic MiniMed 640G system able to improve it? Preliminary insights

Journal

Clinical Diabetology

Issue

Vol 6, No 1 (2017)

Pages

1-7

Published online

2017-06-20

DOI

10.5603/DK.2017.0002

Pubmed

12376491

Bibliographic record

Clinical Diabetology 2017;6(1):1-7.

Keywords

hypoglycemia
quality of life
sensor- -augmented pump therapy
SmartGuard technology

Authors

Aleksandra Tabor
Władysław Bartosz Gaweł
Oliwia Goik
Grażyna Deja
Przemysława Jarosz-Chobot

References (23)
  1. Cyganek K, Małecki MT. Zastosowanie ciągłego monitorowania glikemii u chorych na cukrzycę — przegląd dostępnych systemów. Diabetologia Praktyczna. 2010; 11(5): 167–172.
  2. New JP, Ajjan R, Pfeiffer AFH, et al. Continuous glucose monitoring in people with diabetes: the randomized controlled Glucose Level Awareness in Diabetes Study (GLADIS). Diabet Med. 2015; 32(5): 609–617.
  3. SYSTEM MINIMED Pompa insulinowa MiniMed® Veo™. https://www.pompy-medtronic.pl/system-minimed/pompy-insulinowe-minimed-veo (November 27, 2016).
  4. SYSTEM MINIMED Pompa insulinowa MiniMed® 640G™. https://www.pompy-medtronic.pl/system-minimed/pompy-insulinowe-minimed-640g (November 27, 2016).
  5. De Bock MI, George CE, et al. Performance of a predictive insulin pump suspension algorithm for prevention of overnight hypoglycaemia. Diabetes. 2014: A240–A241.
  6. Choudhary P, Olsen BS, Conget I et al. Performance of the predictive low glucose management feature of the MiniMed 640G system in a user evaluation study. American Diabetes Association 75th Scientific Sessions Boston, USA, 5–9 June 2015.
  7. MAPI RESEARCH TRUST. http://mapi-trust.org/ (November 27, 2016).
  8. Ly TT, Maahs DM, Rewers A, et al. Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatric Diabetes. 2014; 15(S20): 180–192.
  9. Driscoll KA, Raymond J, Naranjo D, et al. Fear of Hypoglycemia in Children and Adolescents and Their Parents with Type 1 Diabetes. Curr Diab Rep. 2016; 16(8): 77.
  10. Tamborlane WV, Swan K, Sikes KA, et al. The renaissance of insulin pump treatment in childhood type 1 diabetes. Rev Endocr Metab Disord. 2006; 7(3): 205–213.
  11. Haugstvedt A, Wentzel-Larsen T, Graue M, et al. Fear of hypoglycaemia in mothers and fathers of children with Type 1 diabetes is associated with poor glycaemic control and parental emotional distress: a population-based study. Diabet Med. 2010; 27(1): 72–78.
  12. Mauras N, Beck R, Xing D, et al. Diabetes Research in Children Network (DirecNet) Study Group. A randomized clinical trial to assess the efficacy and safety of real-time continuous glucose monitoring in the management of type 1 diabetes in young children aged 4 to< 10 years. Diabetes Care. 2012; 35(2): 204–210.
  13. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. N Eng J Med. 2010; 363(4): 311–320.
  14. Keenan DB, Mastrototaro JJ, Zisser H, et al. Accuracy of the Enlite 6-day glucose sensor with guardian and Veo calibration algorithms. Diabetes Technol Ther. 2012; 14(3): 225–231.
  15. Evans K, Richardson C, Landry A, et al. Experience With the Enlite Sensor in a Multicenter Pediatric Study. The Diabetes Educator. 2015; 41(1): 31–37.
  16. Streisand R, Swift E, Wickmark T, et al. Pediatric parenting stress among parents of children with type 1 diabetes: the role of self-efficacy, responsibility, and fear. J Pediatr Psychol. 2005; 30(6): 513–521.
  17. Valenzuela JM, Patino AM, McCullough J, et al. Insulin pump therapy and health-related quality of life in children and adolescents with type 1 diabetes. J Pediatr Psychol. 2006; 31(6): 650–660.
  18. Peyser T, Dassau E, Breton M, et al. The artificial pancreas: current status and future prospects in the management of diabetes. Ann N Y Acad Sci. 2014; 1311: 102–123.
  19. Cobelli C, Renard E, Kovatchev B. Artificial pancreas: past, present, future. Diabetes. 2011; 60(11): 2672–2682.
  20. Kumareswaran K, Evans ML, Hovorka R. Closed-loop insulin delivery: towards improved diabetes care. Discov Med. 2012; 13(69): 159–170.
  21. Peyser T, Dassau E, Breton M, et al. The artificial pancreas: current status and future prospects in the management of diabetes. Ann N Y Acad Sci. 2014; 1311: 102–123.
  22. Ly TT, Nicholas JA, Retterath A, et al. Effect of Sensor-Augmented Insulin Pump Therapy and Automated Insulin Suspension vs Standard Insulin Pump Therapy on Hypoglycemia in Patients With Type 1 Diabetes A Randomized Clinical Trial. JAMA. 2013; 310(12): 1240–1247.
  23. Zhong A, Choudhary P, McMahon C, et al. Effectiveness of Automated Insulin Management Features of the MiniMed(®) 640G Sensor-Augmented Insulin Pump. Diabetes Technol Ther. 2016; 18(10): 657–663.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl